Send to:

Choose Destination
See comment in PubMed Commons below
Trends Parasitol. 2003 Mar;19(3):115-20.

Can primaquine therapy for vivax malaria be improved?

Author information

  • 1US Naval Medical Research Unit #2, American Embassy Jakarta, Fleet Post Office, Asia-Pacific 96520-8132, USA.


The incidence and range of endemic malaria caused by Plasmodium vivax has expanded during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent reservoir of infection. Primaquine (PQ), introduced 50 years ago, is the only drug available to eliminate hypnozoites. However, lengthy treatment courses and follow-up periods are not conducive to assessing the effectiveness of this drug in preventing relapses. Resistance to standard therapy could be widespread. Studies are urgently needed to gauge this problem and to determine the safety, tolerability and efficacy of shorter courses and higher doses of PQ.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk